Hwang Kun, Kim Hun, Kim Hyung Mook, Kim Joo Ho
Department of Plastic Surgery, Inha University School of Medicine, Incheon, Korea.
Department of Plastic Surgery, Inha University Hospital, Incheon, Korea.
Eplasty. 2021 Mar 8;21:e4. eCollection 2021.
The aim of this study was to determine the odds ratio of anaplastic large-cell lymphoma in late seroma formation. In a PubMed search, 415 articles were found using the terms "breast implant AND seroma" (n = 232), "breast implant AND effusion" (n = 42), and "anaplastic large cell lymphoma AND breast (n = 141). Sixty-seven abstracts were read, and 27 full articles were reviewed. Three articles reported the incidence of late seroma in breast implants, with a total of 75 seromas out of 48,211 implants (0.16%). One article reported 48 cases of non-Hodgkin lymphoma from 43,537 implants (0.11%). Another article reported that 11 patients had anaplastic large-cell lymphoma among 389 primary lymphoma of the breast (2.83%). Two articles reported 143 seromas out of 236 anaplastic large-cell lymphomas (60.59%). The risk of anaplastic large-cell lymphoma was significantly higher in the patients having late seroma than those without seroma (odds ratio = 998.93; 95% confidence interval, 768.90-1297.78; < .001). The incidence of anaplastic large-cell lymphoma in seroma was calculated by dividing the number of anaplastic large cell lymphomas with seroma (n = 143) by total seroma (N = 11,843), which resulted in an incidence of 1.21%. The expected incidence of anaplastic large-cell lymphoma in seroma was 1.21%. If late seroma develops after breast implant insertion, ultrasonography-guided aspiration should be performed, with enzyme-linked-immunosorbent serologic assay for CD30.
本研究的目的是确定晚期血清肿形成时间变性大细胞淋巴瘤的比值比。在PubMed搜索中，使用“乳房植入物AND血清肿”（n = 232）、“乳房植入物AND积液”（n = 42）和“间变性大细胞淋巴瘤AND乳房”（n = 141）等术语共找到415篇文章。阅读了67篇摘要，并对27篇全文进行了综述。三篇文章报道了乳房植入物晚期血清肿的发生率，在48,211个植入物中共75例血清肿（0.16%）。一篇文章报道了43,537个植入物中有48例非霍奇金淋巴瘤（0.11%）。另一篇文章报道在389例原发性乳房淋巴瘤中有11例患者发生间变性大细胞淋巴瘤（2.83%）。两篇文章报道在236例间变性大细胞淋巴瘤中有143例血清肿（60.59%）。发生晚期血清肿的患者发生间变性大细胞淋巴瘤的风险显著高于未发生血清肿的患者（比值比 = 998.93；95%置信区间，768.90 - 1297.78；P <.001）。血清肿中间变性大细胞淋巴瘤的发生率通过血清肿伴间变性大细胞淋巴瘤的数量（n = 143）除以血清肿总数（N = 11,843）计算得出，结果为1.21%。血清肿中间变性大细胞淋巴瘤的预期发生率为1.21%。如果乳房植入物插入后出现晚期血清肿，应进行超声引导下抽吸，并进行CD30的酶联免疫吸附血清学检测。
